Moleculin Targets accelerated FDA approval of WP1732; Pursues Development for Ocular Tumors
June 12 2018 - 7:30AM
Moleculin Biotech, Inc. (Nasdaq:MBRX) ("Moleculin" or the
"Company"), a clinical stage pharmaceutical company focused on the
development of oncology drug candidates, all of which are based on
license agreements with The University of Texas System on behalf of
the M.D. Anderson Cancer Center, today announced that it has
entered into an agreement with the Jagiellonian University in
Krakow, Poland, for the development of its STAT3 inhibitor, WP1732,
for the treatment of ocular tumors.
“Today there are very limited options for the
treatment of ocular tumors," commented Walter Klemp, Chairman and
CEO of Moleculin. “And, these tumors are believed to involve a
significant upregulation of the activated form of STAT3. It
is important to note that, in addition to the ability of WP1732 to
inhibit the proliferation and survival of cancer cells in
preclinical studies, as STAT3 inhibitor, it is designed to potently
block cancer stem cells and induce immune system function to
overcome tumor-induced immune tolerance. This could make
WP1732 an ideal candidate for targeting these unique and highly
metastatic tumors.”
Mr. Klemp continued: “We remain committed to
targeting accelerated approval pathways for WP1732 by focusing on
significant unmet needs. This includes niche indications like
ocular tumors and AML, as well as high-profile indications like
pancreatic cancer.”
About Moleculin Biotech, Inc.
Moleculin Biotech, Inc. is a clinical stage
pharmaceutical company focused on the development f oncology drug
candidates, all of which are based on discoveries made at M.D.
Anderson Cancer Center. Our clinical stage drugs are Annamycin, an
anthracycline designed to avoid multidrug resistance mechanisms
with little to no cardiotoxicity being studied for the treatment of
relapsed or refractory acute myeloid leukemia, more commonly
referred to as AML, and WP1066, an immuno-stimulating STAT3
inhibitor targeting brain tumors, pancreatic cancer and AML. We are
also engaged in preclinical development of additional drug
candidates, including additional STAT3 inhibitors and compounds
targeting the metabolism of tumors.
For more information about the Company, please visit
http://www.moleculin.com.
Forward-Looking Statements
Some of the statements in this release are
forward-looking statements within the meaning of Section 27A of the
Securities Act of 1933, Section 21E of the Securities Exchange Act
of 1934 and the Private Securities Litigation Reform Act of 1995,
which involve risks and uncertainties. Forward-looking statements
in this press release include, without limitation, the ability of
WP1732 to demonstrate safety and efficacy in the treatment of
ocular tumors, AML, pancreatic and other cancers and the ability of
WP1732 to qualify for an accelerated approval pathway. These
statements relate to future events, future expectations, plans and
prospects. Although Moleculin Biotech believes that the
expectations reflected in such forward-looking statements are
reasonable as of the date made, expectations may prove to have been
materially different from the results expressed or implied by such
forward-looking statements. Moleculin Biotech has attempted to
identify forward-looking statements by terminology including
''believes,'' ''estimates,'' ''anticipates,'' ''expects,''
''plans,'' ''projects,'' ''intends,'' ''potential,'' ''may,''
''could,'' ''might,'' ''will,'' ''should,'' ''approximately'' or
other words that convey uncertainty of future events or outcomes to
identify these forward-looking statements. These statements are
only predictions and involve known and unknown risks,
uncertainties, and other factors, including those discussed under
Item 1A. "Risk Factors" in our most recently filed Form 10-K filed
with the Securities and Exchange Commission (“SEC”) and updated
from time to time in our Form 10-Q filings and in our other public
filings with the SEC. Any forward-looking statements
contained in this release speak only as of its date. We undertake
no obligation to update any forward-looking statements contained in
this release to reflect events or circumstances occurring after its
date or to reflect the occurrence of unanticipated events.
ContactsJoe Dorame, Robert Blum or Joe
DiazLytham Partners, LLC602-889-9700mbrx@lythampartners.com
Moleculin Biotech (NASDAQ:MBRX)
Historical Stock Chart
From Mar 2024 to Apr 2024
Moleculin Biotech (NASDAQ:MBRX)
Historical Stock Chart
From Apr 2023 to Apr 2024